Figure 2.
Risk for relapse in AML and MDS patients with HLA ligands present or missing for donor-inhibitory KIR. Cumulative incidence estimates for the probability of relapse in (A) AML patients and (B) AML and MDS patients.
Risk for relapse in AML and MDS patients with HLA ligands present or missing for donor-inhibitory KIR. Cumulative incidence estimates for the probability of relapse in (A) AML patients and (B) AML and MDS patients.
